After the human genome sequence was decoded in the early 21st century, high-throughput genomics technology has been growing remarkably. It is now possible to analyze the genotype of hundreds of thousands of single nucleotide polymorphisms (SNPs) at a low cost and in a short time with the advancement of technology in large-capacity SNP microarray chips. A genome-wide association study (GWAS) carried out using the SNP chip, and it suggested genetic biomarkers that affect clinical phenotype based on statistical significance among hundreds of thousands of SNPs present on the chip. However, there are several problems with GWAS analyses. First, approximately 90% of the genetic variants discovered through a GWAS are located in the non-coding or intergenic regions. Most SNPs are not functional genetic mutations that affect the phenotype of a gene. Second, the effect size (fenestration) of genetic variation discovered through GWAS is usually small. Further, the odds ratio for certain diseases is robust in the disease cohort but not high enough in the general population.
In the current issue of
Clinical and Molecular Hepatology, Ting et al. [
1]. validated that
HSD17B13 (rs72613567 and rs6834314) variants showed an inverse association with non-alcoholic fatty liver disease (NAFLD) in the Chinese population but not in Malays or Indians. The study provided several important insights. First, the
HSD17B13 variant also has an inverse relationship with NAFLD in Asians. A more interesting finding is that the effects of
HSD17B13 variants were different among Asian ethnicities. Not only the prevalence of SNPs but also the effect size of SNPs differs according to ethnic background. Therefore, it is important to validate the influence of SNPs on ethnic differences. The study showed that the protective effects of
HSD17B13 variants in Asians were different from those in Chinese, Malays, and Indians. Second, a GWAS study analyzed hundreds of thousands of genes at the same time, so statistical errors may occur; it may sometimes be difficult to match the control group. Therefore, caution should be exercised when accepting the odds ratio obtained in a cross-sectional study as a risk factor. GWAS methodology needs to be validated before the results of prospective cohort studies are accepted as determining risk factors. Here, the first such longitudinal cohort study performed in Asia is presented.
Some SNPs show high penetration with a 70–80% probability of disease development, but NAFLD does not develop because of just one SNP. Most SNPs associated with metabolic diseases showed low fenestration of approximately 1.5–2.5-fold. Therefore, it has been suggested that a genetic risk score (GRS) should be generated to enhance risk prediction using genetic data. Gellert-Kristensen et al. [
2] proposed a new GRS for NAFLD comprising three common variants (PNPLA3, TM6SF2, and
HSD17B13); this GRS predicts a 12-fold higher risk of cirrhosis compare to general population. Koo et al. [
3] suggested a polygenic risk score based on polymorphisms in PNPLA3 and TM6SF2 together with clinical factors that identified steatohepatitis among fatty liver disease. The presence of an SNP variant does not necessarily mean that the disease will develop in near future. Rather, environmental factors such as smoking, lack of exercise, overeating, and alcohol consumption are more important factors that cause NAFLD. Therefore, genetic and environmental risk factors should be properly integrated and taken into consideration when evaluating patients with NAFLD.
FOOTNOTES
-
Conflicts of Interest: The author has no conflicts to disclose.
Abbreviations
genome-wide association study
nonalcoholic fatty liver disease
single nucleotide polymorphisms
REFERENCES
- 1. Ting YW, Kong AS, Zain SM, Chan WK, Tan HL, Mohamed Z, et al. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: results from a multi-ethnic Asian cohort. Clin Mol Hepatol 2021 Feb 23;doi: 10.3350/cmh.2020.0162.
- 2. Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 2020;72:845-856.
- 3. Koo BK, Joo SK, Kim D, Lee S, Bae JM, Park JH, et al. Development and validation of a scoring system, based on genetic and clinical factors, to determine risk of steatohepatitis in Asian patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020;18:2592-2599.e10.
Citations
Citations to this article as recorded by
- Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef - Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef - Risk factors in nonalcoholic fatty liver disease
Eunji Ko, Eileen L. Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(Suppl): S79. CrossRef - Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Jung Hwan Yu, Han Ah Lee, Seung Up Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef - Advances in genetic variation in metabolism-related fatty liver disease
Fan Shi, Mei Zhao, Shudan Zheng, Lihong Zheng, Haiqiang Wang
Frontiers in Genetics.2023;[Epub] CrossRef - Fatty liver disease: An updated overview of risk factors
Abdullatif Suliman Alsayegh, Mohammed Abdullah Alduaybi, Hamoud Ghayyadh Alanizi, Nada Abdulrahman Amer Alajmi, Shahad Mohammed Bin Saeed, Meshal Ibrahim Zaid Al Owias, Adel Awad Al Rashedi, Asma Saad Alqahtani, Bader Sayah Alanezi
International journal of health sciences.2023; 7(S1): 3698. CrossRef
